{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:42:04Z","timestamp":1740120124947,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12185-023-03680-1","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T04:30:50Z","timestamp":1702355450000},"page":"50-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma"],"prefix":"10.1007","volume":"119","author":[{"given":"Akio","family":"Onishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Matsumura-Kimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Isa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoji","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-1550","authenticated-orcid":false,"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Kyoto Clinical Hematology Study Group investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"issue":"7","key":"3680_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/biomedicines10071464","volume":"10","author":"N Bellamkonda","year":"2022","unstructured":"Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune response to SARS-CoV-2 vaccines. Biomedicines. 2022;10(7):1464. https:\/\/doi.org\/10.3390\/biomedicines10071464.","journal-title":"Biomedicines"},{"issue":"18","key":"3680_CR2","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.3390\/ijms231810374","volume":"23","author":"M Federico","year":"2022","unstructured":"Federico M. How Do Anti-SARS-CoV-2 mRNA vaccines protect from severe disease? Int J Mol Sci. 2022;23(18):10374. https:\/\/doi.org\/10.3390\/ijms231810374.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3680_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJ Pessoa de Magalh\u00e3es","year":"2013","unstructured":"Pessoa de Magalh\u00e3es RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garc\u00eda-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79\u201386. https:\/\/doi.org\/10.3324\/haematol.2012.067272. (Epub 2012 Jul 6).","journal-title":"Haematologica"},{"issue":"1","key":"3680_CR4","doi-asserted-by":"publisher","first-page":"16294","DOI":"10.1038\/s41598-022-20747-x","volume":"12","author":"A Sugiyama","year":"2022","unstructured":"Sugiyama A, Kurisu A, Nagashima S, Hando K, Saipova K, Akhmedova S, et al. Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. Sci Rep. 2022;12(1):16294. https:\/\/doi.org\/10.1038\/s41598-022-20747-x.","journal-title":"Sci Rep"},{"issue":"11","key":"3680_CR5","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/cid\/ciac292","volume":"75","author":"H Maeda","year":"2022","unstructured":"Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022;75(11):1971\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac292.","journal-title":"Clin Infect Dis"},{"key":"3680_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858399.eCollection","volume":"13","author":"M Oyaert","year":"2022","unstructured":"Oyaert M, De Scheerder MA, Van Herrewege S, Laureys G, Van Assche S, Cambron M, et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front Immunol. 2022;13: 858399. https:\/\/doi.org\/10.3389\/fimmu.2022.858399.eCollection.","journal-title":"Front Immunol"},{"key":"3680_CR7","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. https:\/\/doi.org\/10.1136\/bmj-2021-068632.","journal-title":"BMJ"},{"key":"3680_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/IDR.S396271.eCollection","volume":"16","author":"A Onishi","year":"2023","unstructured":"Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, et al. Impact of Treatment with Anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti\u2013SARS\u2013CoV\u20132 Vaccination in Mature B-Cell Neoplasms. Infection and Drug Resistance. 2023;16:509\u201319. https:\/\/doi.org\/10.2147\/IDR.S396271.eCollection.","journal-title":"Infection and Drug Resistance"},{"issue":"1","key":"3680_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2014","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2014;100(1):107\u201313. https:\/\/doi.org\/10.3324\/haematol.2014.107714. (Epub 2014 Oct 24).","journal-title":"Haematologica"},{"issue":"26","key":"3680_CR10","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/blood.2020008150","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033\u201340. https:\/\/doi.org\/10.1182\/blood.2020008150.","journal-title":"Blood"},{"issue":"12","key":"3680_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41408-021-00588-z","volume":"11","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Mu\u00f1oz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11(12):198. https:\/\/doi.org\/10.1038\/s41408-021-00588-z.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3680_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.572.eCollection","volume":"5","author":"Y Kaneko","year":"2022","unstructured":"Kaneko Y, Sugiyama A, Tanaka T, Fukui K, Taguchi A, Tatsuno K, et al. The serological diversity of serum IgG\/IgA\/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. Health Sci Rep. 2022;5(3): e572. https:\/\/doi.org\/10.1002\/hsr2.572.eCollection.","journal-title":"Health Sci Rep"},{"issue":"1","key":"3680_CR13","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/s41598-021-81629-2","volume":"11","author":"C Jeewandara","year":"2021","unstructured":"Jeewandara C, Jayathilaka D, Gomes L, Wijewickrama A, Narangoda E, Idampitiya D, et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep. 2021;11(1):2062. https:\/\/doi.org\/10.1038\/s41598-021-81629-2.","journal-title":"Sci Rep"},{"issue":"1","key":"3680_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","volume":"12","author":"EHY Lau","year":"2021","unstructured":"Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63. https:\/\/doi.org\/10.1038\/s41467-020-20247-4.","journal-title":"Nat Commun"},{"issue":"2","key":"3680_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41423-020-00588-2","volume":"18","author":"V Legros","year":"2021","unstructured":"Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318\u201327. https:\/\/doi.org\/10.1038\/s41423-020-00588-2. (Epub 2021 Jan 6).","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"3680_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2012","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2012;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244. (Epub 2012 Dec 3).","journal-title":"Bone Marrow Transplant"},{"key":"3680_CR17","unstructured":"Global Change Data Lab. Oxford Martin School. Coronavirus (COVID-19) Vaccinations-Our World in Data. https:\/\/ourworldindata.org\/covid-vaccinations"},{"issue":"18","key":"3680_CR18","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1002\/cncr.34354","volume":"128","author":"TA Ollila","year":"2022","unstructured":"Ollila TA, Masel RH, Reagan JL, Lu S, Rogers RD, Paiva KJ, et al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022;128(18):3319\u201329. https:\/\/doi.org\/10.1002\/cncr.34354. (Epub 2022 Jul 11).","journal-title":"Cancer"},{"key":"3680_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892331.eCollection","volume":"13","author":"SP Pascale","year":"2022","unstructured":"Pascale SP, Nuccorini R, Pierri T, Di Mare R, Fabio L, Lerose E, et al. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients. Front Immunol. 2022;13: 892331. https:\/\/doi.org\/10.3389\/fimmu.2022.892331.eCollection.","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"3680_CR20","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/S2152-2650(22)01335-0","volume":"22","author":"F St-Pierre","year":"2022","unstructured":"St-Pierre F, Doukas P, Boyer J, Nieves M, Ma S. CLL-211 Humoral immune response following COVID-19 vaccination in patients with chronic lymphocytic leukemia (CLL) and indolent non-hodgkin lymphoma (NHL): results from a large, single-center observational study. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S273. https:\/\/doi.org\/10.1016\/S2152-2650(22)01335-0.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"3680_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.vaccine.2022.01.040","volume":"40","author":"M Tanguay","year":"2022","unstructured":"Tanguay M, Boutin M, Laumaea A, Salaciak M, Mendoza A, Cassis C, et al. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 2022;40(9):1203\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.040. (Epub 2022 Jan 24).","journal-title":"Vaccine"},{"issue":"24","key":"3680_CR22","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/bloodadvances.2022008530","volume":"6","author":"N Chuleerarux","year":"2022","unstructured":"Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates OS, Hirankarn N, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022;6(24):6198\u2013207. https:\/\/doi.org\/10.1182\/bloodadvances.2022008530.","journal-title":"Blood Adv"},{"issue":"6","key":"3680_CR23","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1172\/JCI111921","volume":"75","author":"LM Pilarski","year":"1985","unstructured":"Pilarski LM, Ruether BA, Mant MJ. Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels. J Clin Invest. 1985;75(6):2024\u20139. https:\/\/doi.org\/10.1172\/JCI111921.","journal-title":"J Clin Invest"},{"key":"3680_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2014.00257.eCollection","volume":"5","author":"SM Tete","year":"2014","unstructured":"Tete SM, Bijl M, Sahota SS, Bos NA. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol. 2014;5:257. https:\/\/doi.org\/10.3389\/fimmu.2014.00257.eCollection.","journal-title":"Front Immunol"},{"issue":"5","key":"3680_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12185-022-03305-z","volume":"115","author":"K Narita","year":"2022","unstructured":"Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115(5):728\u201336. https:\/\/doi.org\/10.1007\/s12185-022-03305-z. (Epub 2022 Feb 21).","journal-title":"Int J Hematol"},{"key":"3680_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1472-6890-8-13","volume":"8","author":"H Olteanu","year":"2008","unstructured":"Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol. 2008;8:13. https:\/\/doi.org\/10.1186\/1472-6890-8-13.","journal-title":"BMC Clin Pathol"},{"issue":"3","key":"3680_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/09612033231151603","volume":"32","author":"JA Reynolds","year":"2023","unstructured":"Reynolds JA, Faustini SE, Tosounidou S, Plant T, Ubhi M, Gilman R, et al. Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE. Lupus. 2023;32(3):431\u20137. https:\/\/doi.org\/10.1177\/09612033231151603. (Epub 2023 Jan 11).","journal-title":"Lupus"},{"issue":"37","key":"3680_CR28","doi-asserted-by":"publisher","first-page":"13463","DOI":"10.1073\/pnas.1410980111","volume":"111","author":"SR Bidgood","year":"2014","unstructured":"Bidgood SR, Tam JC, McEwan WA, Mallery DL, James LC. Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells. Proc Natl Acad Sci USA. 2014;111(37):13463\u20138. https:\/\/doi.org\/10.1073\/pnas.1410980111. (Epub 2014 Aug 28).","journal-title":"Proc Natl Acad Sci USA"},{"key":"3680_CR29","doi-asserted-by":"publisher","first-page":"127105","DOI":"10.1016\/j.micres.2022.127105","volume":"263","author":"VV Rangel-Ram\u00edrez","year":"2022","unstructured":"Rangel-Ram\u00edrez VV, Mac\u00edas-Pi\u00f1a KA, Servin-Garrido RR, de Alba-Aguayo DR, Moreno-Fierros L, Rubio-Infante N. A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: is there a role for IgA in COVID-19 diagnosis or severity? Microbiol Res. 2022;263:127105. https:\/\/doi.org\/10.1016\/j.micres.2022.127105.","journal-title":"Microbiol Res"},{"issue":"5","key":"3680_CR30","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.4049\/jimmunol.175.5.3262","volume":"175","author":"Y Shi","year":"2005","unstructured":"Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol. 2005;175(5):3262\u20137. https:\/\/doi.org\/10.4049\/jimmunol.175.5.3262.","journal-title":"J Immunol"},{"issue":"10","key":"3680_CR31","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/vaccines10101601","volume":"10","author":"DA Jolliffe","year":"2022","unstructured":"Jolliffe DA, Faustini SE, Holt H, Perdek N, Maltby S, Talaei M, et al. Determinants of Antibody Responses to SARS-CoV-2 Vaccines: population-Based Longitudinal Study (COVIDENCE UK). Vaccines (Basel). 2022;10(10):1601. https:\/\/doi.org\/10.3390\/vaccines10101601.","journal-title":"Vaccines (Basel)"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03680-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03680-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03680-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:27:00Z","timestamp":1704457620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03680-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3680"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03680-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"3 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM has received honoraria from Janssen Pharmaceutical and Ono Pharmaceutical; TF has received honoraria from Takeda Pharmaceutical; TT has received honoraria from Bristol Myers Squibb (BMS), Janssen Pharmaceutical, Sanofi, Kyowa Kirin, and Chugai Pharmaceutical; YS has received honoraria from Ono Pharmaceutical, BMS, Janssen Pharmaceutical, Sanofi, Kyowa Kirin, Takeda Pharmaceutical, and Chugai Pharmaceutical; SM has received honoraria from Sanofi and Ono Pharmaceutical; DN has received honoraria from Janssen Pharmaceutical and Chugai Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Sanofi, and Janssen Pharmaceutical; and NU has received honoraria from BMS and Takeda. JK is a consultant for Janssen Pharmaceutical and BMS; has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, Takeda Pharmaceutical, Mochida Pharmaceutical, and BMS; and has received honoraria from Janssen Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, BMS, and Takeda Pharmaceutical. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki, and the institutional review board approved the study protocol of each participating institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from all the subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}